Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 14.09B | 14.20B | 13.12B | 12.17B | 16.07B | 8.50B |
Gross Profit | 11.96B | 12.23B | 11.30B | 10.61B | 13.63B | 7.38B |
EBITDA | 4.98B | 5.32B | 4.69B | 5.34B | 9.28B | 3.90B |
Net Income | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B |
Balance Sheet | ||||||
Total Assets | 37.55B | 37.76B | 33.08B | 29.21B | 25.43B | 17.16B |
Cash, Cash Equivalents and Short-Term Investments | 8.35B | 9.01B | 10.84B | 14.33B | 12.53B | 6.72B |
Total Debt | 2.70B | 2.70B | 2.70B | 2.70B | 2.70B | 2.70B |
Total Liabilities | 8.16B | 8.41B | 7.11B | 6.55B | 6.67B | 6.14B |
Stockholders Equity | 29.39B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B |
Cash Flow | ||||||
Free Cash Flow | 3.02B | 3.66B | 3.67B | 4.42B | 6.53B | 2.00B |
Operating Cash Flow | 3.95B | 4.42B | 4.59B | 5.01B | 7.08B | 2.62B |
Investing Cash Flow | -133.50M | -2.47B | -3.19B | -3.78B | -5.38B | -70.60M |
Financing Cash Flow | -3.34B | -2.20B | -1.79B | -1.01B | -1.01B | -1.97B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $13.10B | 212.62 | 0.47% | ― | 17.13% | -88.78% | |
72 Outperform | $59.14B | 13.94 | 15.96% | 0.64% | 7.52% | 15.65% | |
72 Outperform | $13.20B | 12.27 | 22.69% | ― | 25.11% | 46.46% | |
68 Neutral | $33.22B | 40.55 | 17.33% | ― | 78.01% | ― | |
66 Neutral | $41.40B | ― | -414.62% | ― | 17.21% | 21.16% | |
58 Neutral | $26.87B | ― | -3.87% | ― | 0.58% | -764.64% | |
46 Neutral | C$200.35M | -3.25 | -23.22% | 2.71% | 21.07% | -1.26% |
At the 2025 Annual Meeting of Shareholders held on June 13, Regeneron Pharmaceuticals’ shareholders voted on several key proposals. The election of Class I directors was confirmed, with nominees set to serve until the 2028 meeting. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. Additionally, an advisory vote approved the executive compensation package. A significant amendment to declassify the board of directors was passed, while proposals to eliminate supermajority vote requirements for certain amendments to the company’s Certificate of Incorporation were not approved.
The most recent analyst rating on (REGN) stock is a Hold with a $940.00 price target. To see the full list of analyst forecasts on Regeneron stock, see the REGN Stock Forecast page.